🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vivek Verma

University of Minnesota

ORCID: 0000-0001-8129-4140

Also affiliated with The University of Texas MD Anderson Cancer Center, Hormel (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC”.

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC

The Lancet Oncology(2022)10.1016/s1470-2045(22)00134-6
N/A
0.385DataRank · unranked
12 citations

Vivek Verma, James W Welsh, Silvia C Formenti, Joe Y Chang

Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal

European Journal of Cancer(2024)10.1016/j.ejca.2024.113972
N/A
0.385DataRank · unranked
12 citations

Vivek Verma, Ralph R. Weichselbaum, Joe Y. Chang

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w
N/A
0.312DataRank · unranked
7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-013074
N/A
0.241DataRank · unranked
4 citations

Eman Showkatian, Vivek Verma, Qasem Al-Tashi, Muhammad Aminu, Xinyan Xu +17 more

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

Nature Immunology(2020)10.1038/s41590-020-00818-9
N/A
0DataRank · unranked
181 citations

Nazli Jafarzadeh, Shannon K. Boi, Subhadip Kundu, Zhinuo Jiang, Yiping Fan +16 more

Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy

Cell Metabolism(2025)10.1016/j.cmet.2025.03.003
N/A
0DataRank · unranked
35 citations

Jignesh Soni, Jin Lu, Anil Kumar Yadav, Shivani Bansal, Tian Mi +6 more

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Cancer Immunology Research(2022)10.1158/2326-6066.cir-21-0457
N/A
0DataRank · unranked
26 citations

Vivek Verma, Pankaj Gaur, Veerupaxagouda Patil, Xingdong Yang, Zainab Ramlaoui +8 more

Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells

Frontiers in Microbiomes(2022)10.3389/frmbi.2022.1049688
N/A
0DataRank · unranked
7 citations

Vivek Verma, Maddie McDermott, Pal Koak, Fábia de Oliveira Andrade, Leena Hilakivi‐Clarke

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-006533
N/A
0DataRank · unranked
20 citations

David A. Braun, Aitziber Buqué, Sarah B. Gitto, Jennifer L. Guerriero, Brendan Horton +9 more